What is Asimov?
Asimov is at the forefront of synthetic biology, building a comprehensive genetic design platform engineered to program living cells. By integrating genetic engineering, design automation, and artificial intelligence, Asimov aims to unlock novel applications in critical sectors such as molecular manufacturing and advanced therapeutics. The company's multi-disciplinary approach positions it as a key player in the rapidly evolving field of biotechnology, seeking to translate complex biological systems into programmable tools for industrial and medical breakthroughs.
How much funding has Asimov raised?
Asimov has raised a total of $179.7M across 2 funding rounds:
Angel/Seed
$4.7M
Series B
$175M
Angel/Seed (2017): $4.7M with participation from Andreessen Horowitz
Series B (2023): $175M led by KDT Solutions, Casdin Capital, Fidelity Investments, and CPP Investments
Key Investors in Asimov
KDT Solutions
KDT Solutions is an IT solutions provider with over 30 years of experience, specializing in practical, growth-oriented services including computer networking, hardware, software, and security. They focus on building lasting client relationships and managing vendor relationships to support business operations.
Casdin Capital
Casdin Capital, founded in 2011, is a venture capital firm with deep expertise in financing life science innovations, particularly in diagnostics and molecular information. They have backed numerous pioneering companies in the sector.
Fidelity Investments
Fidelity Investments is a global financial services and investment resources provider, assisting individuals and institutions in achieving their financial objectives through a wide range of investment products and services.
What's next for Asimov?
The recent major strategic investment signifies a pivotal moment for Asimov, likely enabling the company to accelerate its research and development initiatives, scale its operations, and expand its market reach. This substantial backing suggests a transition towards commercialization and broader application of its genetic design platform. Asimov is poised to further solidify its position in the synthetic biology landscape, potentially driving innovation in areas requiring precise cellular programming and advanced biological manufacturing.
See full Asimov company page
